drugset / Trial / NCT00253500

Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

NCT00253500 ↗

Phase 2 Completed 15 enrolled Case Comprehensive Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving epirubicin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well epirubicin works in treating women who are undergoing surgery for stage I, stage II, or stage III breast cancer.

Timeline

Start
2002-06
Primary completion
2005-09
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule 120 mg Intravenous
Background Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous

Indications